Figure 1
Figure 2
Figure 3
Figure 4
Patient, tumor, and treatment characteristics for 65 patients (70 tumors) receiving stereotactic ablative radiotherapy (SABR)
| Characteristic | Value Values are median (range) or No. of patients/tumors (%). |
|---|---|
| Age, year | 64 (22–95) |
| Men | 50 (77) |
| Primary cancer | |
| Lung | 49 (70) |
| Colorectal | 10 (14) |
| Other (breast, gastric, melanoma, germ cell, RCC) | 11 (16) |
| Treatment indication | |
| Primary lung (medically inoperable T1–T2) | 12 (17) |
| Relapse (primary lung and oligometastatic) | 24 (34) |
| Oligometastatic | 34 (49) |
| Previous radiation to chest | 20 (29) |
| Tumor location | |
| ≤ 1 cm from tracheobronchial tree | 24 (34) |
| > 1 cm but ≤ 2 cm from tracheobronchial tree | 12 (17) |
| Lesions intersecting mediastinum | 22 (31) |
| ≤ 1 cm from thoracic aorta | 12 (17) |
| Left laterality | 37 (53) |
| Lesion size (PTV), cc | 33.4 (7.3–461.5) |
| Total dose, Gy | 55 (30–60) |
| Dose per fraction, Gy | 9.75 (4–18) |
| Fractions | 5 (3–10) |
| BED10, Gy | 110 (48–151.2) |
| BED10 | |
| < 100 Gy | 16 (23) |
| ≥ 100 Gy | 54 (77) |
| BED3, Gy | 228 (90–378) |
| Treatment time, days | 10 (5–19) |
| Treatment time | |
| < 10 days | 30 (43) |
| ≥ 10 days | 40 (57) |
| Treatment on consecutive days | 6 (9) |
Tumor and patient outcomes after stereotactic ablative radiotherapy (SABR) for central lung tumors
| Characteristic | Value Values are No. patients/tumors (%) or No. patients unless otherwise stated. |
|---|---|
| Response on 3-month PET/CT after SABR | |
| Complete response | 43 (61) |
| Partial response | 19 (27) |
| Progression | 2 (3) |
| Unknown (patient died before 3 months or imaging not performed) | 6 (9) |
| Locoregional control | |
| 2-year | 84% |
| 5-year | 70% |
| Median | Not reached |
| Overall survival | |
| 2-year | 52% |
| 5-year | 28% |
| Median | 28 months |
| 2-Year toxicity-free survival | 81% |
| All Toxicities (grade 2 or higher) | 17 (26.2%) |
| RT-induced pneumonitis | 9 (13.8%) |
| Brachial and recurrent laryngeal nerve injury | 3 (4.6%) |
| Esophagitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |
| Toxicity, grade 5 (fatal) | 5 (7.7%) |
| RT-induced pneumonitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |